Lawyers for patients suing Johnson & Johnson and Bayer allege that the companies misled editors at The New England Journal of Medicine about the safety of rivaroxaban (Xarelto), the New York Times reports. 

During the third quarter of fiscal year 2016, Medtronic’s revenue increased six percent to $6.394 billion, while its diluted earnings per share decreased one percent to $0.77 per share.

For the fourth quarter of fiscal year 2016, Medtronic will increase its cash dividend by 25 percent to $0.38 per ordinary share, the company announced on Feb. 19.

Stryker Corporation agreed to buy Physio-Control International on Feb. 16 for $1.28 billion in an all-cash deal.

Healthcare Information and Management Systems Society (HIMSS) Analytics has published a report on some of the technologies shaping hospitals’ purchase plans in 2016.

Edwards Lifesciences announced on Feb. 4 that it had agreed to repurchase $325 million of its common stock from Morgan Stanley & Co. Edwards is funding the accelerated share repurchase using available cash, according to a news release.

For the fourth quarter of 2015, Boston Scientific’s sales hit $1.978 billion, representing a 10 percent jump in operational revenue compared with the same time period the previous year, while its adjusted earnings per share increased from $0.22 to $0.26.

Merit Medical Systems announced this week that it has purchased the HeRO Graft vascular access system and its related assets from CryoLife for $18.5 million.